Difference between revisions of "CNS5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(7 intermediate revisions by the same user not shown) | |||
Line 5: | Line 5: | ||
If empty (no name is present), please volunteer to create content for that disease! | If empty (no name is present), please volunteer to create content for that disease! | ||
− | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest. | + | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> |
− | |||
− | <br /> | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | |+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | ||
Line 19: | Line 17: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
− | | | + | |CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[CNS5:Astrocytoma,_IDH-mutant|Astrocytoma, IDH-mutant]] | ||
|Disease | |Disease | ||
|Meenakshi Mehrotra | |Meenakshi Mehrotra | ||
Line 30: | Line 48: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Oligodendroglioma, IDH- | + | |[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] |
+ | |Disease | ||
+ | |Riley Lochner (trainee), Shashi Shetty (mentor) | ||
|6/7/2022 | |6/7/2022 | ||
| | | | ||
Line 39: | Line 59: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Glioblastoma, IDH- | + | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] |
+ | |Disease | ||
+ | |Meenakshi Mehrotra | ||
| | | | ||
| | | | ||
Line 46: | Line 68: | ||
|LS | |LS | ||
| | | | ||
− | |Moved from " | + | |Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added |
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_astrocytoma,_MYB-_or_MYBL1-altered|Diffuse astrocytoma, MYB- or MYBL1-altered]] |
+ | |Disease | ||
+ | |Scott Smith | ||
|6/27/2023 | |6/27/2023 | ||
| | | | ||
Line 57: | Line 81: | ||
|2021 template added (page created 6/27/23) | |2021 template added (page created 6/27/23) | ||
|- | |- | ||
− | |Angiocentric | + | |[[CNS5:Angiocentric_glioma|Angiocentric glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 66: | Line 92: | ||
| | | | ||
|- | |- | ||
− | |Polymorphous | + | |[[CNS5:Polymorphous_low-grade_neuroepithelial_tumour_of_the_young|Polymorphous low-grade neuroepithelial tumour of the young]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 75: | Line 103: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_low-grade_glioma,_MAPK_pathway-altered_|Diffuse low-grade glioma, MAPK pathway-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 84: | Line 114: | ||
| | | | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] |
+ | |Disease | ||
+ | |Laveniya Satgunaseelan (Linda Cooley - previous version) | ||
| | | | ||
| | | | ||
Line 93: | Line 125: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_hemispheric_glioma,_H3_G34-mutant|Diffuse hemispheric glioma, H3 G34-mutant]] |
+ | |Disease | ||
+ | |Xiaolin (Lynn) Hu | ||
|2/21/2022 | |2/21/2022 | ||
| | | | ||
Line 102: | Line 136: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Diffuse | + | |[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]] |
+ | |Disease | ||
+ | |Madina Sukhanova | ||
|10/28/2022 | |10/28/2022 | ||
| | | | ||
Line 111: | Line 147: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Infant- | + | |[[CNS5:Infant-type_hemispheric_glioma|Infant-type hemispheric glioma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
| | | | ||
| | | | ||
Line 118: | Line 157: | ||
| | | | ||
| | | | ||
− | |||
|- | |- | ||
− | |Pilocytic | + | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] |
+ | |Disease | ||
+ | |Jeremy Pulvers | ||
|9/13/2022<br /> | |9/13/2022<br /> | ||
| | | | ||
Line 129: | Line 169: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |High- | + | |[[CNS5:High-grade_astrocytoma_with_piloid_features|High-grade astrocytoma with piloid features]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 138: | Line 180: | ||
| | | | ||
|- | |- | ||
− | |Pleomorphic | + | |[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 147: | Line 191: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Subependymal | + | |[[CNS5:Subependymal_giant_cell_astrocytoma|Subependymal giant cell astrocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 156: | Line 202: | ||
| | | | ||
|- | |- | ||
− | |Chordoid | + | |[[CNS5:Chordoid_glioma|Chordoid glioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 165: | Line 213: | ||
| | | | ||
|- | |- | ||
− | |Astroblastoma, MN1- | + | |[[CNS5:Astroblastoma,_MN1-altered|Astroblastoma, MN1-altered]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 174: | Line 224: | ||
| | | | ||
|- | |- | ||
− | |Ganglioglioma||Disease | + | |[[CNS5:Ganglioglioma|Ganglioglioma]] |
+ | |Disease | ||
+ | |Leila Moayed-Aloei | ||
|6/30/2022 | |6/30/2022 | ||
| | | | ||
Line 183: | Line 235: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Gangliocytoma||Disease|| | + | |[[CNS5:Gangliocytoma|Gangliocytoma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 192: | Line 257: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Dysembryoplastic_neuroepithelial_tumour|Dysembryoplastic neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 201: | Line 268: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Diffuse_glioneuronal_tumour_with_oligodendroglioma-like_features_and_nuclear_clusters|Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 210: | Line 279: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_glioneuronal_tumour|Papillary glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 219: | Line 290: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Rosette-forming_glioneuronal_tumour|Rosette-forming glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 228: | Line 301: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Myxoid_glioneuronal_tumour|Myxoid glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 237: | Line 312: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 246: | Line 323: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 255: | Line 334: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Dysplastic_cerebellar_gangliocytoma_(Lhermitte-Duclos_disease)|Dysplastic cerebellar gangliocytoma (Lhermitte-Duclos disease)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 264: | Line 345: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Central_neurocytoma|Central neurocytoma]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 273: | Line 367: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cerebellar_liponeurocytoma|Cerebellar liponeurocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 282: | Line 378: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Supratentorial_ependymoma|Supratentorial ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 291: | Line 389: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Supratentorial_ependymoma,_ZFTA_fusion-positive_|Supratentorial ependymoma, ZFTA fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 300: | Line 400: | ||
| | | | ||
|- | |- | ||
− | |Supratentorial | + | |[[CNS5:Supratentorial_ependymoma,_YAP1_fusion-positive|Supratentorial ependymoma, YAP1 fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 309: | Line 411: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Posterior_fossa_ependymoma|Posterior fossa ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 318: | Line 422: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Posterior_fossa_group_A_(PFA)_ependymoma|Posterior fossa group A (PFA) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 327: | Line 433: | ||
| | | | ||
|- | |- | ||
− | |Posterior | + | |[[CNS5:Posterior_fossa_group_B_(PFB)_ependymoma|Posterior fossa group B (PFB) ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 336: | Line 444: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Spinal_ependymoma|Spinal ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 345: | Line 455: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Spinal_ependymoma,_MYCN-amplified|Spinal ependymoma, MYCN-amplified]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 354: | Line 466: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 363: | Line 477: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Subependymoma|Subependymoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 372: | Line 488: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 3 (CHOROID PLEXUS TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Choroid_plexus_papilloma|Choroid plexus papilloma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 390: | Line 519: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_choroid_plexus_papilloma|Atypical choroid plexus papilloma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 399: | Line 530: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Choroid_plexus_carcinoma|Choroid plexus carcinoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 408: | Line 541: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 4 (EMBRYONAL TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |Medulloblastoma, WNT- | + | |[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] |
+ | |Disease | ||
+ | |Lisa Lansdon, PhD (LGG trainee just finished), Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | ||
|9/20/21 | |9/20/21 | ||
| | | | ||
Line 426: | Line 572: | ||
|2021 template added | |2021 template added | ||
|- | |- | ||
− | |Medulloblastoma, SHH- | + | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-wildtype|Medulloblastoma, SHH-activated and TP53-wildtype]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Medulloblastoma,_histologically_defined|Medulloblastoma, histologically defined]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 435: | Line 616: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Atypical_teratoid/rhabdoid_tumour|Atypical teratoid/rhabdoid tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 444: | Line 627: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cribriform_neuroepithelial_tumour|Cribriform neuroepithelial tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 453: | Line 638: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Embryonal_tumour_with_multilayered_rosettes|Embryonal tumour with multilayered rosettes]] |
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_neuroblastoma,_FOXR2-activated|CNS neuroblastoma, FOXR2-activated]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_tumour_with_BCOR_internal_tandem_duplication|CNS tumour with BCOR internal tandem duplication]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:CNS_embryonal_tumour_NEC/NOS|CNS embryonal tumour NEC/NOS]] | ||
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 462: | Line 682: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 5 (PINEAL TUMOURS) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineocytoma|Pineocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 480: | Line 713: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 489: | Line 724: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pineoblastoma|Pineoblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 498: | Line 735: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_tumour_of_the_pineal_region|Papillary tumour of the pineal region]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 507: | Line 746: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Desmoplastic_myxoid_tumour_of_the_pineal_region,_SMARCB1-mutant|Desmoplastic myxoid tumour of the pineal region, SMARCB1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 516: | Line 757: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Schwannoma|Schwannoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 534: | Line 788: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Neurofibroma|Neurofibroma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 543: | Line 799: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Perineurioma|Perineurioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 552: | Line 810: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Hybrid_nerve_sheath_tumours|Hybrid nerve sheath tumours]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 561: | Line 821: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 570: | Line 832: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 579: | Line 843: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Cauda_equina_neuroendocrine_tumour_(previously_paraganglioma)|Cauda equina neuroendocrine tumour (previously paraganglioma)]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 588: | Line 854: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 7 (MENINGIOMA) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Meningioma|Meningioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 606: | Line 885: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Solitary_fibrous_tumour|Solitary fibrous tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 624: | Line 916: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangiomas_and_vascular_malformations|Haemangiomas and vascular malformations]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 633: | Line 927: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Haemangioblastoma|Haemangioblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 642: | Line 938: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Rhabdomyosarcoma|Rhabdomyosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 651: | Line 949: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Intracranial_mesenchymal_tumour,_FET::CREB_fusion-positive|Intracranial mesenchymal tumour, FET::CREB fusion-positive]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 660: | Line 960: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 669: | Line 971: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Primary_intracranial_sarcoma,_DICER1-mutant|Primary intracranial sarcoma, DICER1-mutant]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 678: | Line 982: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Ewing_sarcoma|Ewing sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 687: | Line 993: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 696: | Line 1,004: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chondrosarcoma|Chondrosarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 705: | Line 1,015: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Chordoma|Chordoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 714: | Line 1,026: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 9 (MELANOCYTIC TUMOURS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Diffuse_meningeal_melanocytic_neoplasms:_Melanocytosis_and_melanomatosis|Diffuse meningeal melanocytic neoplasms: Melanocytosis and melanomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 732: | Line 1,057: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Circumscribed_meningeal_melanocytic_neoplasms:_Melanocytoma_and_melanoma|Circumscribed meningeal melanocytic neoplasms: Melanocytoma and melanoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 741: | Line 1,068: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS) |
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |Primary | + | |[[CNS5:Primary_diffuse_large_B-cell_lymphoma_of_the_CNS|Primary diffuse large B-cell lymphoma of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 759: | Line 1,099: | ||
| | | | ||
|- | |- | ||
− | |Immunodeficiency- | + | |[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 768: | Line 1,110: | ||
| | | | ||
|- | |- | ||
− | |Lymphomatoid | + | |[[CNS5:Lymphomatoid_granulomatosis|Lymphomatoid granulomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 777: | Line 1,121: | ||
| | | | ||
|- | |- | ||
− | |Intravascular | + | |[[CNS5:Intravascular_large_B-cell_lymphoma|Intravascular large B-cell lymphoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 786: | Line 1,132: | ||
| | | | ||
|- | |- | ||
− | |MALT | + | |[[CNS5:MALT_lymphoma_of_the_dura|MALT lymphoma of the dura]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 795: | Line 1,143: | ||
| | | | ||
|- | |- | ||
− | |Other | + | |[[CNS5:Other_low-grade_B-cell_lymphomas_of_the_CNS|Other low-grade B-cell lymphomas of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 804: | Line 1,154: | ||
| | | | ||
|- | |- | ||
− | |Anaplastic | + | |[[CNS5:Anaplastic_large_cell_lymphoma_(ALK+/ALK−)|Anaplastic large cell lymphoma (ALK+/ALK−)]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 811: | Line 1,163: | ||
|MS | |MS | ||
| | | | ||
− | |2021 template added | + | |2021 template added; Did not yet convert to CNS5 namespace. Should Jennie instead do the related two pages in HAEM5 of "[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]" and "[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma - Compendium of Cancer Genome Aberrations (ccga.io)]]"? |
+ | |- | ||
+ | |[[CNS5:T-cell_and_NK/T-cell_lymphomas|T-cell and NK/T-cell lymphomas]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Erdheim-Chester_disease|Erdheim-Chester disease]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[CNS5:Juvenile_xanthogranuloma|Juvenile xanthogranuloma]] | ||
+ | |Disease | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 822: | Line 1,220: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Histiocytic_sarcoma|Histiocytic sarcoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 831: | Line 1,231: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 11 (GERM CELL TUMOURS) |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Germ_cell_tumours_of_the_CNS|Germ cell tumours of the CNS]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 849: | Line 1,262: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 12 (TUMOURS OF THE SELLAR REGION |
+ | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Adamantinomatous_craniopharyngioma|Adamantinomatous craniopharyngioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 867: | Line 1,293: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Papillary_craniopharyngioma|Papillary craniopharyngioma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 876: | Line 1,304: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituicytoma,_granular_cell_tumour_of_the_sellar_region,_and_spindle_cell_oncocytoma|Pituicytoma, granular cell tumour of the sellar region, and spindle cell oncocytoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 885: | Line 1,315: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_adenoma_/_pituitary_neuroendocrine_tumour|Pituitary adenoma / pituitary neuroendocrine tumour]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 894: | Line 1,326: | ||
| | | | ||
|- | |- | ||
− | | | + | |[[CNS5:Pituitary_blastoma|Pituitary blastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 903: | Line 1,337: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 13 (METASTASES TO THE CNS) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | | | + | |[[CNS5:Metastases_to_the_brain_and_spinal_cord_parenchyma|Metastases to the brain and spinal cord parenchyma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 921: | Line 1,368: | ||
| | | | ||
|- | |- | ||
− | |Metastases to the | + | |[[CNS5:Metastases_to_the_meninges|Metastases to the meninges]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 930: | Line 1,379: | ||
| | | | ||
|- | |- | ||
− | | | + | |CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS) |
+ | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | | | ||
+ | ---- | ||
|- | |- | ||
− | |Neurofibromatosis | + | |[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] |
+ | |Disease | ||
+ | |Ngoni Faya (trainee) + Madina Sukhanova | ||
| | | | ||
| | | | ||
Line 948: | Line 1,410: | ||
|NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Neurofibromatosis Type 1 (NF1)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Neurofibromatosis | + | |[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 957: | Line 1,421: | ||
| | | | ||
|- | |- | ||
− | |Schwannomatosis||Disease | + | |[[CNS5:Schwannomatosis|Schwannomatosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 966: | Line 1,432: | ||
| | | | ||
|- | |- | ||
− | |Von Hippel-Lindau | + | |[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 975: | Line 1,443: | ||
| | | | ||
|- | |- | ||
− | |Tuberous | + | |[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 984: | Line 1,454: | ||
| | | | ||
|- | |- | ||
− | |Li-Fraumeni | + | |[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 993: | Line 1,465: | ||
| | | | ||
|- | |- | ||
− | |Cowden | + | |[[CNS5:Cowden_syndrome|Cowden syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,002: | Line 1,476: | ||
| | | | ||
|- | |- | ||
− | |Constitutional | + | |[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 1,011: | Line 1,487: | ||
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]] |
+ | |Disease | ||
+ | |Jennifer Laffin | ||
|8/22/2023 | |8/22/2023 | ||
| | | | ||
Line 1,020: | Line 1,498: | ||
|NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "Constitutional Mismatch Repair Deficiency (CMMRD) Syndrome (MLH1, PMS2, MSH2, MSH6)" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Naevoid | + | |[[CNS5:Naevoid_basal_cell_carcinoma_syndrome|Naevoid basal cell carcinoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,029: | Line 1,509: | ||
| | | | ||
|- | |- | ||
− | |Rhabdoid | + | |[[CNS5:Rhabdoid_tumour_predisposition_syndrome|Rhabdoid tumour predisposition syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,038: | Line 1,520: | ||
| | | | ||
|- | |- | ||
− | |Carney | + | |[[CNS5:Carney_complex|Carney complex]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,047: | Line 1,531: | ||
| | | | ||
|- | |- | ||
− | |DICER1 | + | |[[CNS5:DICER1_syndrome|DICER1 syndrome]] |
+ | |Disease | ||
+ | |Jennie Thurston | ||
|7/2/2023 | |7/2/2023 | ||
| | | | ||
Line 1,056: | Line 1,542: | ||
|NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | |NOT YET CREATED - See page "''DICER1''-Related Tumour Predisposition Syndrome (''DICER1'')" in GTS5 book to finish first. Then will make this page for this other book to refer to GTS5 page and include this body site's specific content. | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,065: | Line 1,553: | ||
| | | | ||
|- | |- | ||
− | |Melanoma- | + | |[[CNS5:Melanoma-astrocytoma_syndrome|Melanoma-astrocytoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,074: | Line 1,564: | ||
| | | | ||
|- | |- | ||
− | |Familial | + | |[[CNS5:Familial_retinoblastoma|Familial retinoblastoma]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,083: | Line 1,575: | ||
| | | | ||
|- | |- | ||
− | |BAP1 | + | |[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,092: | Line 1,586: | ||
| | | | ||
|- | |- | ||
− | |Fanconi | + | |[[CNS5:Fanconi_anaemia|Fanconi anaemia]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,101: | Line 1,597: | ||
| | | | ||
|- | |- | ||
− | |ELP1- | + | |[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] |
+ | |Disease | ||
+ | | | ||
| | | | ||
| | | | ||
Line 1,110: | Line 1,608: | ||
| | | | ||
|- | |- | ||
− | |} | + | |} |
Latest revision as of 14:00, 25 February 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.